Winter 2022 (Volume 32, Number 4)
Update from the Therapeutics Committee
By Alison Kydd, MD, PhD, FRCPC
Over the past year, the CRA Therapeutics Committee
has continued to work on issues related
to COVID-19. We have also been working on
new initiatives for the CRA involving the review and approval
of Canadian Agency for Drugs and Technologies
in Health (CADTH) submissions for rheumatic medications.
Some of the highlights over the past year include
Updates on the CRA Position Statement on
COVID-19 Vaccination — last updated in March 2022
- Communication sent to CRA members on May 10th
regarding triamcinolone and Depo-Medrol shortages.
- E-blast sent to members Sept 9th regarding the
triamcinolone hexacetonide shelf-life extension
- Communications with Amgen regarding changes in
access to Enbrel for pediatric patients.
- Development of a review process for CADTH
clinician input applications for submission by the
- CRA Position Statements on Biosimilars and Citrate-Free Adalimumab — published in November 2022.
- Work on a provincial framework to aid with
communication and dissemination of information
regarding drug access issues.
- Initial meetings regarding the development of
a Drug Access and Adjudication (Pharmacare)
Monitoring drug shortages and advocating for CRA
members and their patients are always our top priorities.
We will continue to respond to emerging issues on behalf
of our members through position statements.
This work is only possible through the dedication
of our volunteer committee members, who are all very
busy with their numerous other roles. They have been
highly committed and have always impressed me with
their quick response and expert guidance. My Co-Chair
Rosie Scuccimarri and I greatly appreciate their ongoing
support. We have recently added trainee member Glynis
Byrne and look forward to her involvement on the
committee. In addition, we have recently welcomed
Sarah Webster, a CRA staff member, who is proving to be
excellent in her new role. We send a heartfelt thanks to
Sue Ranta who worked with our committee for a number
Alison Kydd, MD, PhD, FRCPC
Co-chair, CRA Therapeutics Committee
Clinical Associate Professor, Rheumatology
University of British Columbia
Vancouver, British Columbia